Efficacy of a triamcinolone acetonide-loaded dissolving microneedle patch for the treatment of hypertrophic scars and keloids: a randomized, double-blinded, placebo-controlled split-scar study

Disphanurat, Wareeporn; Sivapornpan, Nakarin; Srisantithum, Benjaporn; Leelawattanachai, Jeerapond

doi:10.1007/s00403-022-02473-6

Cited by 10 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intralesional injection causes pain to the patients. Various administration methods of therapeutic drugs, including the enhancement of transdermal delivery, have been developed to enable targeted delivery with reduced pain, as follows: the co-injection of lidocaine using an electric syringe [506], the topical application of lidocaine [507,508], the use of cryoanesthesia [509], the use of a needlefree pneumatic jet-injection [120], microneedle patches [510] and so on. The transdermal iontophoretic delivery of medicine will not cause any pain, and the dosage formulations for poorly soluble compounds like corticosteroids can be modified as follows: use of a mixture of organic solvent and water [511], using nanostructured lipid carriers as vehicles [512], and using solid lipid nanoparticles hydrogel [513].…”

Section: Effect Of Treatment Techniquesmentioning

confidence: 99%

Pharmacotherapy for Keloids and Hypertrophic Scars

Murakami,

Shigeki

2024

IJMS

View full text Add to dashboard Cite

Keloids (KD) and hypertrophic scars (HTS), which are quite raised and pigmented and have increased vascularization and cellularity, are formed due to the impaired healing process of cutaneous injuries in some individuals having family history and genetic factors. These scars decrease the quality of life (QOL) of patients greatly, due to the pain, itching, contracture, cosmetic problems, and so on, depending on the location of the scars. Treatment/prevention that will satisfy patients’ QOL is still under development. In this article, we review pharmacotherapy for treating KD and HTS, including the prevention of postsurgical recurrence (especially KD). Pharmacotherapy involves monotherapy using a single drug and combination pharmacotherapy using multiple drugs, where drugs are administered orally, topically and/or through intralesional injection. In addition, pharmacotherapy for KD/HTS is sometimes combined with surgical excision and/or with physical therapy such as cryotherapy, laser therapy, radiotherapy including brachytherapy, and silicone gel/sheeting. The results regarding the clinical effectiveness of each mono-pharmacotherapy for KD/HTS are not always consistent but rather scattered among researchers. Multimodal combination pharmacotherapy that targets multiple sites simultaneously is more effective than mono-pharmacotherapy. The literature was searched using PubMed, Google Scholar, and Online search engines.

show abstract

Section: Effect Of Treatment Techniquesmentioning

confidence: 99%

Pharmacotherapy for Keloids and Hypertrophic Scars

Murakami,

Shigeki

2024

IJMS

View full text Add to dashboard Cite

show abstract

“…[ 18 ] Similar results were obtained on MNP loaded with TA. [ 45,121 ] Four weeks after stopping treatment, the size of the keloid returned to baseline, while the pain did not reoccur demonstrating the effectiveness of MNP application in keloid patients. [ 45 ] With the assistance of ultrasound, a more effective drug release can be achieved to control keloid.…”

Section: Therapeutic Applications Of Mnps In Scarsmentioning

confidence: 99%

Targeting Diverse Wounds and Scars: Recent Innovative Bio‐design of Microneedle Patch for Comprehensive Management

Zhuang,

Wang,

Feng

et al. 2023

Small

View full text Add to dashboard Cite

Wounds and the subsequent formation of scars constitute a unified and complex phased process. Effective treatment is crucial; however, the diverse therapeutic approaches for different wounds and scars, as well as varying treatment needs at different stages, present significant challenges in selecting appropriate interventions. Microneedle patch (MNP), as a novel minimally invasive transdermal drug delivery system, has the potential for integrated and programmed treatment of various diseases and has shown promising applications in different types of wounds and scars. In this comprehensive review, the latest applications and biotechnological innovations of MNPs in these fields are thoroughly explored, summarizing their powerful abilities to accelerate healing, inhibit scar formation, and manage related symptoms. Moreover, potential applications in various scenarios are discussed. Additionally, the side effects, manufacturing processes, and material selection to explore the clinical translational potential are investigated. This groundwork can provide a theoretical basis and serve as a catalyst for future innovations in the pursuit of favorable therapeutic options for skin tissue regeneration.

show abstract

“…The injection is the primary therapeutic approach for HS treatment 10 . The primary clinical intervention involves the intralesional administration of glucocorticoids, with triamcinolone acetonide (TA) being the most commonly employed glucocorticoid since 1960 11,12 . The intense pain caused by the high pressure during injection administration is unbearable for most patients, even with anesthesia, leading to poor patient compliance 13 .…”

Section: Introductionmentioning

confidence: 99%

Paper battery powered iontophoresis microneedles patch for hypertrophic scar treatment

Jiang,

Gao,

Chen

et al. 2024

Preprint

View full text Add to dashboard Cite

Hypertrophic scar (HS) is a plaque fibrous and indurated dermal lesion that may cause physical, psychological, and cosmetic challenges for patients. Intralesional injection of triamcinolone acetonide (TA) is commonly used in clinical practice, which cause unbearable pain and uneven drug delivery within HS tissue. Herein, we developed a paper battery powered iontophoresis-driven microneedle patch (PBIMNP) for self-management and painless treatment of HS. The high integration of PBIMNP was achieved by incorporating a paper battery as the power source for iontophoresis. The transdermal drug delivery strategy of PBIMNP combined microneedles and iontophoresis techniques, involving "pressing and poking, phase transformation, and diffusion and iontophoresis", which can actively deliver 90.19% drug into the HS tissue with excellent in vitro drug permeation performance. PBIMNP administration effectively reduced the mRNA and protein levels, leading to a decrease in the expression of TGF-β1 and Col I associated with HS formation, demonstrating its efficacy in HS treatment. The painless microneedles and wearable design endow the PBIMNP as a highly promising platform for self-administration on HS treatment.

show abstract

Efficacy of a triamcinolone acetonide-loaded dissolving microneedle patch for the treatment of hypertrophic scars and keloids: a randomized, double-blinded, placebo-controlled split-scar study

Cited by 10 publications

References 32 publications

Pharmacotherapy for Keloids and Hypertrophic Scars

Pharmacotherapy for Keloids and Hypertrophic Scars

Targeting Diverse Wounds and Scars: Recent Innovative Bio‐design of Microneedle Patch for Comprehensive Management

Paper battery powered iontophoresis microneedles patch for hypertrophic scar treatment

Contact Info

Product

Resources

About